Table 1.
Characteristics of the UK Biobank total study population , as well as stratified in cases and controls
| Characteristics | Total | Cases | Controls |
|---|---|---|---|
| Number of participants | 309,780 | 36,391 | 273,389 |
| Age at inclusion, years | 56.8 (8.0) | 61.1 (6.4) | 56.2 (8.0) |
| Sex, % men | 46 | 66 | 43 |
| BMI (kg/m2) | 27.4 (4.8) | 29.0 (5.0) | 27.2 (4.7) |
| Fasting serum concentrations (mmol/L) | |||
| TG (median (IQR)) | 1.49 (1.1) | 1.72 (1.25) | 1.46 (1.08) |
| Total cholesterol | 5.71 (1.14) | 5.25 (1.28) | 5.77 (1.11) |
| LDL-cholesterol | 3.47(0.87) | 3.27 (0.97) | 3.61 (0.85) |
| HDL-cholesterol | 1.45 (0.38) | 1.30 (0.35) | 1.47 (0.38) |
| LDL-C GRS (median (IQR)) | 0.41 (0.30) | 0.39 (0.30) | 0.41 (0.30) |
| aLPL GRS (median (IQR)) | 0.09 (0.20) | 0.09 (0.20) | 0.09 (0.23) |
| APOA5 GRS (median (IQR)) | 0.86 (0.00) | 0.86 (0.00) | 0.86 (0.00) |
In stratified analyses, the number of cases and controls varies per genotype group.
Values are mean (SD), unless otherwise specified. GRS unit is in SD.
GRS, genetic risk score; IQR, interquartile range.
a
Due to unavailability of rs301, the LPL GRS for the UK Biobank was calculated based on five variants (rs268, rs326, rs328, and rs10096633) versus the six variants (rs268, rs301, rs326, rs328, and rs10096633) used in the NEO and OBB cohorts.